Jan De Witte has served as ResMed’s director since May 2019, and is a member of its audit and compliance oversight committees.
Mr. De Witte is President, CEO, and a director of Integra LifeSciences (NASDAQ: IART), a global leader in regenerative tissue technologies and neurosurgical solutions.
Mr. De Witte serves on the board of directors of the Advanced Medical Technology Association (AdvaMed). From 2018 until 2022, Mr. De Witte served as chair of the board of Hangar K, a non-profit innovation and co-creation hub bringing together start-ups, young growth companies, and established companies in the Flanders (Belgium) region with the aim to accelerate innovation and growth, with a focus on digital technologies in EdTech and GameTech. Over that same period, he also served as a board member of Ghent University (Belgium).
Mr. De Witte has served in a variety of operational and business leadership roles over the past 30 years. Most recently, he served as CEO and a member of the board of directors of Barco (EBR: BAR), a global leader in advanced visualization solutions for healthcare, entertainment, and enterprise, with headquarters in Belgium. Before joining Barco in October 2016, Mr. De Witte was an officer of the General Electric Company (NYSE: GE), and CEO of its healthcare division’s software and solutions business. During his 17-year tenure with GE, he worked in management and CEO roles in manufacturing, supply chain, quality/lean six sigma, services, and software solutions, covering business responsibilities across Europe, Middle East, China, Asia-Pacific, and the Americas. While at GE, he and his family lived in Belgium, London, Chicago, Milwaukee, and Paris.
Before GE, Mr. De Witte held operational management positions in supply chain and manufacturing at Procter & Gamble (NYSE: PG) in Europe. He also served as senior consultant with McKinsey & Company serving clients in the airline, process, and high-tech industries across Europe.
Mr. De Witte holds a Master of Science degree in electromechanical engineering with Greatest Distinction from the KU Leuven in Belgium, and an MBA from Harvard Business School.
What is Jan De Witte's net worth?
The estimated net worth of Jan De Witte is at least $1.64 million as of November 12th, 2024. Mr. De Witte owns 6,723 shares of ResMed stock worth more than $1,638,933 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. De Witte may own. Learn More about Jan De Witte's net worth.
How do I contact Jan De Witte?
Has Jan De Witte been buying or selling shares of ResMed?
In the last ninety days, Jan De Witte has sold $198,052.76 of ResMed stock. Most recently, Witte Jan De sold 796 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a transaction totalling $198,052.76. Following the completion of the sale, the director now directly owns 6,723 shares of the company's stock, valued at $1,672,749.63. Learn More on Jan De Witte's trading history.
Who are ResMed's active insiders?
ResMed's insider roster includes Carol Burt (Director), Jan De Witte (Director), Robert Douglas (COO), Karen Drexler (Director), Michael Farrell (CEO), Peter Farrell (Director), Kaushik Ghoshal (Insider), James Hollingshead (Insider), Justin Leong (Insider), David Pendarvis (Insider), Michael Rider (General Counsel), Brett Sandercock (CFO), Rajwant Sodhi (Insider), and Ronald Taylor (Director). Learn More on ResMed's active insiders.
Are insiders buying or selling shares of ResMed?
In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 187,789 shares worth more than $41,061,987.20. The most recent insider tranaction occured on November, 12th when Director Witte Jan De sold 796 shares worth more than $198,052.76. Insiders at ResMed own 0.7% of the company.
Learn More about insider trades at ResMed. Information on this page was last updated on 11/12/2024.
